Medical Condition News

RSS

Scientists uncover genes that govern male and female behaviors

Hormones shape our bodies, make us fertile, excite our most basic urges, and as scientists have known for years, they govern the behaviors that separate men from women. But how? Now a team of scientists at the University of California, San Francisco (UCSF) has uncovered many genes influenced by the male and female sex hormones testosterone and estrogen that, in turn, govern several specific types of male and female behaviors in mice.

3 Feb 2012

Researchers tease out toxic role of tau oligomers in Alzheimer's

One of the most distinctive signs of the development of Alzheimer's disease is a change in the behavior of a protein that neuroscientists call tau. In normal brains, tau is present in individual units essential to neuron health. In the cells of Alzheimer's brains, by contrast, tau proteins aggregate into twisted structures known as "neurofibrillary tangles."

3 Feb 2012

Study to determine causes and impact of hyperkyphosis

The Institute for Aging Research of Hebrew SeniorLife, an affiliate of Harvard Medical School, today announced that Dr. Lisa Samelson and the Institute were awarded a $2.7 million grant from the National Institute on Aging to conduct a five-year study to better understand the cause of hyperkyphosis, a condition that causes extreme forward curvature of the spine.

3 Feb 2012

Rituximab shows promise against primary biliary cirrhosis

An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis (PBC) who had an incomplete response to the standard ursodeoxycholic acid (UDCA) therapy, also known as Ursodiol.

3 Feb 2012

Multiple DNA repair defect in monocytes

Scientists working with Professor Bernd Kaina of the Institute of Toxicology at the Medical Center of Johannes Gutenberg University Mainz have demonstrated for the first time that certain cells circulating in human blood - so-called monocytes - are extremely sensitive to reactive oxygen species (ROS).

3 Feb 2012

EUSA Pharma acquires ASPAREC development and commercialization rights

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma.

3 Feb 2012

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA (sitagliptin), with extended-release metformin.

3 Feb 2012

Silver as effective as leading chemotherapy drugs

The internet is awash with stories of how silver can be used to treat cancer. Now, lab tests have shown that it is as effective as the leading chemotherapy drug - and may have fewer side-effects.

3 Feb 2012

New England Journal of Medicine publishes Diamyd Medical's antigen-based diabetes therapy study

An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association's 71st Scientific Sessions in San Diego, California, USA, on June 28, 2011.

3 Feb 2012

$Heart failure associated with 30% increase in major fractures$

Heart failure associated with 30% increase in major fractures

Heart failure is associated with a 30 percent increase in major fractures and also identifies a high-risk population that may benefit from increased screening and treatment for osteoporosis, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

3 Feb 2012

Nuvo launches Synera in the U.S.

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced the U. S. launch of Synera.

3 Feb 2012

Researchers caution against over-reliance on CNT in return-to-play decisions

A new study by researchers at Indiana University-Purdue University Columbus and Pace University is critical of the widespread use of computerized neuropsychological tests (CNT) in decisions regarding when athletes can return to play after suffering a concussion.

3 Feb 2012

FDA grants Mylan tentative approval for Atorvastatin Calcium ANDA

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg.

3 Feb 2012

Assay analyzing multiple biomarkers could be valuable aid to diagnose major depression

The initial assessment of a blood test to help diagnose major depressive disorder indicates it may become a useful clinical tool. In a paper published in the journal Molecular Psychiatry, a team including Massachusetts General Hospital (MGH) researchers reports that a test analyzing levels of nine biomarkers accurately distinguished patients diagnosed with depression from control participants without significant false-positive results.

2 Feb 2012

Study finds opening blocked neck arteries with metal stent or surgery equally durable

Opening blocked neck arteries with a metal stent or surgery were equally durable, in research presented at the American Stroke Association's International Stroke Conference 2012.

2 Feb 2012

Treatment with clot-busting drugs safe for patients with wake-up stroke

Clot-busting drugs may be safe for patients who wake up experiencing stroke symptoms, according to preliminary research presented at the American Stroke Association's International Stroke Conference 2012.

2 Feb 2012

Colchicine, another weapon against cancer

Finding a drug that targets only the diseased cells in our body and is otherwise harmless to healthy tissue is a goal for cancer researchers. It's driven the work of Professor Laurence Patterson, Director of the Institute of Cancer Therapeutics at the University of Bradford, and his team of researchers.

2 Feb 2012

Complex PCI: Left Main and CTO Summit to be held Feb. 23-25

The final agenda is now available online for the Complex PCI: Left Main and CTO Summit at http://www.complexpci.com/conference/agenda.html. The Summit is a three-day conference featuring state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions and left main coronary interventions.

2 Feb 2012

Scientists reveal novel mechanism underpinning age-dependent changes to cognitive abilities

New findings, led by neuroscientists at the University of Bristol and published this week in the journal Neurobiology of Aging, reveal a novel mechanism through which the brain may become more reluctant to function as we grow older.

2 Feb 2012

High beta-amyloid levels may affect brain performance in healthy adults

High levels of the protein beta-amyloid in the brain that is associated with Alzheimer's disease may affect brain performance even in healthy adults, according to a study published in the February 1, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

2 Feb 2012